Premium
Thalassemic Trait Prevalence in Patients Affected by Psoriatic Arthritis in Anti‐ TNF Treatment
Author(s) -
Atteno Mariangela,
Costa Luisa,
Vitiello Maria,
Caso Francesco,
Sarnelli Giovanni,
Del Puente Antonio,
Scarpa Raffaele
Publication year - 2014
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.21188
Subject(s) - medicine , psoriatic arthritis , rheumatoid arthritis , polyarthritis , concomitant , arthritis , tumor necrosis factor alpha , gastroenterology
Clinical Development Phases I‐III Regulatory, Quality, Manufacturing Postmarketing Phase IVThalassemic trait ( T hal) is associated with rheumatic disease, particularly a mild form of seronegative polyarthritis resembling rheumatoid arthritis ( RA ), but not with other rheumatic diseases. The aim of this study was to estimate the frequency of Thal in patients with psoriatic arthritis ( PsA ) and to evaluate the efficacy of anti‐tumor necrosis factor alpha ( TNF ‐α) therapy in patients with PsA and Thal. We performed a retrospective study in 321 patients with PsA who started therapy with TNF ‐α blockers. For all patients included in the study, at baseline and every 3 months for the 1 year of follow up, data concerning PsA activity and ferritin levels were registered. In our group of PsA patients, a total of 27 (8%) with concomitant Thal were identified and included in the study. In patients without Thal, all variables improved significantly after 6 months of therapy, while in patients with Thal, the same variables showed a significant decrease after 12 months.: Our study shows that PsA is significantly associated with Thal, but further studies are needed to address this issue. The presence of Thal could be a negative predictor of achieving remission during treatment with TNF ‐α‐blockers.